Clinical trials: Inflammatory Bowel Disease, Ulcerative Colitis Type
Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe
PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)
The purpose of the study is to evaluate the safety, tolerability, and clinical efficacy of PN-943 450 mg twice daily [BID] and PN-943 150 mg BID, compared with placebo BID, in subjects with moderate to severe active Ulcerative…
- Trial name
- NCT04504383
- Testing
- PN-943
- Where
- 122 sites in United States, Austria and 11 more
- Volunteers
- 169 people
- Sponsor
- Protagonist Therapeutics, Inc.
Ulcerative Colitis
Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)
Assess the body's reaction to dose-response relationship for the adalimumab/Methotrexate interaction in subjects with moderately to severely active ulcerative colitis.
- Trial name
- NCT01716039
- Testing
- MTX 12.5, MTX 25, Adalimumab
- Volunteers
- 22 people
- Sponsor
- Alimentiv Inc.
Pyoderma Gangrenosum, Crohn's Disease
Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum. This is a 6 month open label study of an intravenous (IV) medication.
- Conditions
- Pyoderma Gangrenosum, Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
- Trial name
- NCT00791557
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University Hospitals Cleveland Medical Center
Ulcerative Colitis
Moxibustion for Mild and Moderate Ulcerative Colitis
The purpose of this study is to determine whether moxibustion is effective to mild and moderate ulcerative colitis and the effect of moxibustion on metabolism.
- Trial name
- NCT02084186
- Testing
- herb-partitioned moxibustion, bran-partitioned moxibustion
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute of Acupuncture, Moxibustion and Meridian
UC - Ulcerative Colitis, Moderately to Severely Active Ulcerative Colitis
A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis
This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with moderately to severely active ulcerative colitis. A total of 120 subjects are planned to be included.
- Trial name
- D2570-202 (NCT07035041)
- Testing
- D-2570
- Where
- China
- Volunteers
- 120 people
- Sponsor
- InventisBio Co., Ltd
Ulcerative Colitis (UC), Crohn's Disease
A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).Crohn's disease (CD) is a long-lasting condition causing inflammation…
- Trial name
- NCT04254783
- Testing
- Risankizumab, Cytochrome P450 (CYP) Substrates
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 20 people
- Sponsor
- AbbVie
Ulcerative Colitis Acute
Efficacy of Cyclosporine Rescue Therapy in Acute Ulcerative Colitis.
The efficacy and safety of Cyclosporine A as rescue therapy for acute severe ulcerative colitis in long-term follow-up.
- Trial name
- Cyclo (NCT05219656)
- Testing
- Cyclosporine A
- Volunteers
- 182 people
- Sponsor
- Tampere University Hospital
Crohn Disease and Ulcerative Colitis
Evaluation of the Effectiveness of Kits Promonitor-IFX/ADL and Promonitor-Anti-IFX/ADL in Patients With IBD
To establish the efficacy, safety, effectiveness and efficiency of monitoring the levels of anti-TNFα drugs and the levels of antibodies generated against these drugs in the treatment of patients with moderate or severe IBD…
- Trial name
- IBDMonitor (NCT06666569)
- Testing
- Use of the test for treatment optimization
- Where
- Spain
- Volunteers
- 209 people
- Sponsor
- Hospital de Basurto
Inflammatory Bowel Disease, Crohn's Disease
Study of Participants With Crohn's Disease and Ulcerative Colitis in Eastern Europe, Middle East, and North Africa (P08166)
This study is being done to assess the clinical course and treatment options for Crohn's Disease (CD) and ulcerative colitis (UC) in the populations of Eastern Europe, Middle East, and North Africa.
- Conditions
- Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
- Trial name
- NCT01293656
- Testing
- No intervention.
- Sponsor
- Merck Sharp & Dohme LLC
Ulcerative Colitis
Combination of Diet and 5ASA ( 5-aminosalicylic Acid) for Ulcerative Colitis
Combination Therapy with Drug and Diet for Induction of Remission in Mild to Moderate Active Pediatric Ulcerative colitis: A Single Blinded, International Randomized Controlled Trial
- Trial name
- INDUCT (NCT03980405)
- Testing
- Group 1- Control Diet, Group 2- UCD Diet
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Prof. Arie Levine
Inflammatory Bowel Disease
Confocal Endomicroscopy During Endoscopy
The main objective of this study is to determine the role of epithelial cell homeostasis in the pathogenesis of intestinal diseases.
- Trial name
- NCT00988273
- Testing
- Confocal endomicroscopy
- Where
- Canada
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Colitis, Ulcerative
To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis
Japanese patients with moderate or severe active ulcerative colitis as a subject when ozanimod 0.46 mg or 0.92 mg is orally administered is evaluated about dose response, efficacy and safety with placebo as a control.
- Trial name
- NCT03915769
- Testing
- Ozanimod
- Where
- 67 sites in Japan
- Volunteers
- 198 people
- Sponsor
- Celgene
Ulcerative Colitis (UC)
Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis
To evaluate safety and efficacy of two adalimumab dosing regimens for induction and maintenance (standard and higher dosing) in achieving clinical remission in subjects with moderately to severely active ulcerative colitis.
- Trial name
- NCT02065622
- Testing
- Adalimumab
- Where
- 173 sites in United States, Austria and 18 more
- Volunteers
- 952 people
- Sponsor
- AbbVie
Ulcerative Colitis, Inflammatory Bowel Diseases
Russian Extremely Severe Ulcerative Colitis Study
The purpose of this study is prove the need to selection of a extremely severe ulcerative colitis, to identify predictors of colectomy, which will reduce the optimal time for surgery.
- Trial name
- REXs_UC (NCT03947931)
- Where
- Russia
- Volunteers
- 71 people
- Sponsor
- State Scientific Centre of Coloproctology, Russian Federation
Ulcerative Colitis
Define Predictors of Response to Ozanimod in UC Discovering Biomarkers in the Management of Ulcerative Colitis
A diagnostic tool that identifies biomarkers that predict response prior to and during induction of ozanimod will have a major impact on improving outcomes in UC patients.
- Trial name
- NCT05809583
- Testing
- Ozanimod
- Where
- United States
- Sponsor
- Beth Israel Deaconess Medical Center
Ulcerative Colitis, Gastrointestinal Disease
Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis
The purpose of The PROSPECT Study is to evaluate an investigational medication for the treatment of moderate to severe ulcerative colitis.
- Conditions
- Ulcerative Colitis, Gastrointestinal Disease, Inflammatory Bowel Disease
- Trial name
- NCT00073047
- Testing
- Daclizumab
- Where
- 35 sites in United States, Belgium and 1 more
- Volunteers
- 150 people
- Sponsor
- Facet Biotech
Colitis, Ulcerative
Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.
Provide pre-approval single patient Expanded Access (Compassionate Use) of Etrasimod for patients.
- Trial name
- NCT06025227
- Testing
- Etrasimod
- Sponsor
- Pfizer
Ulcerative Colitis
A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)
This study was conducted to determine the efficacy and safety of GWP42003 compared with placebo by the percentage of participants achieving remission quantified as a Mayo score of 2 or less (with no sub-score >1) after 10 weeks…
- Trial name
- NCT01562314
- Testing
- GWP42003
- Where
- 8 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- GW Research Ltd
Inflammatory Bowel Disease, Ulcerative Colitis
Improving Outcomes Among Urgent Care Clinic Patients With Inflammatory Bowel Disease
Inflammatory Bowel Diseases (IBD) refers to a category of disorders, consisting of Crohn's Disease (CD) and Ulcerative Colitis (UC), where segments of the gastrointestinal tract become inflamed and ulcerated.
- Conditions
- Inflammatory Bowel Disease, Ulcerative Colitis, Crohn Disease
- Trial name
- NCT03239704
- Testing
- Telemedicine Follow-Up, Telemedicine Monitoring, 30 Day Comprehensive Questionnaire
- Where
- Canada
- Volunteers
- 450 people
- Sponsor
- Mount Sinai Hospital, Canada
Crohn Disease, Ulcerative Colitis
5-HTP in Patients With IBD in Clinical and Biologic Remission:Effect on Fatigue Scores
This placebo cross-over trial aims to study the effect of the oral intake of an essential amino-acid 5-OH tryptophan, the precursor of serotonin, on the fatigue scores in IBD patients in deep clinical and biological remission.
- Conditions
- Crohn Disease, Ulcerative Colitis, Fatigue, Remission
- Trial name
- TRP-IBD (NCT03574948)
- Testing
- 5-HTP
- Where
- 13 sites in Belgium
- Volunteers
- 175 people
- Sponsor
- University Hospital, Ghent